Products for Research Use Only

ERα17p

CAT: 0804-HY-P10393Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P10393Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ERα17p (ERα 295-311) is the epitope of the CaM binding site on the estrogen receptor α (ER), which interacts with calmodulin (CaM) in a calcium-dependent manner. ERα17p regulates the migration of cancer cells MCF-7, SK-BR-3, T47D, and MDA-MB-231 through Rho/ROCK and PI3K/Akt signaling pathways. ERα17p inhibits proliferations of breast cancer cells, induces apoptosis, and inhibits tumor growth in mouse models[1][2][3].
CAS Number
938077-77-1
Product Name Alternative
ERα (295-311)
UNSPSC
12352209
Target
Apoptosis
Type
Peptides
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/erα17p.html
Smiles
O=C(N[C@@H](CC(C)C)C(N[C@@H](CCSC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CCCCN)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H]([C@H](O)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]1NCCC1
Molecular Formula
C84H154N24O23S
Molecular Weight
1900.33
References & Citations
[1]Kampa M, et al., ERα17p, an ERα P295 -T311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements. J Cell Biochem. 2011 Dec;112 (12) :3786-96. |[2]Bourgoin-Voillard S, et al. Calmodulin association with the synthetic ERα17p peptide investigated by mass spectrometry[J]. International Journal of Mass Spectrometry, 2011, 305 (2-3) : 87-94.|[3]Pelekanou V, et al., The estrogen receptor alpha-derived peptide ERα17p (P (295) -T (311) ) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERα status. Mol Oncol. 2011 Feb;5 (1) :36-47.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported